Clinical Trial Update: Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study [Phase 2]

View source ↗

Summary

Phase 2 DIRECT trial evaluating daratumumab with ibrutinib for relapsed or refractory chronic lymphocytic leukemia was terminated, with results posted in July 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Daratumumab (Darzalex) (daratumumab)
• Ibrutinib (Imbruvica) (Ibrutinib)

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2025-07-01